AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26915674 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast plus montelukast
Number of subjects: 64
Study 26915674 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus montelukast
Number of subjects: 64
Study 25014688 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI group (lopinavir-ritonavir + clinician-selected NRTIs)
Number of subjects: 1277
Study 25014688 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir group (lopinavir-ritonavir + raltegravir)
Number of subjects: 1277
Study 25014688 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy group (protease-inhibitor monotherapy after 12 weeks of induction therapy with raltegravir)
Number of subjects: 1277
Study 25014688 — intervention group
Group type: COMPARATOR
Intervention: NRTI group
Number of subjects: 1277
Study 25014688 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir group
Number of subjects: 1277
Study 25014688 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy group
Number of subjects: 1277
Study 25014688 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1277
Study 22992391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention dose calculation framework and tool applied to PRALIMAP trial data
Number of subjects: 0
Study 20197019 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tablet formulation of nimesulide 100 mg
Number of subjects: 52
Study 20197019 — intervention group
Group type: EXPERIMENTAL
Intervention: Test oral suspension of nimesulide 50 mg/ml
Number of subjects: 52
Study 20197019 — intervention group
Group type: COMPARATOR
Intervention: Nisulid 100 mg tablet
Number of subjects: 52
Study 20197019 — intervention group
Group type: COMPARATOR
Intervention: Nisulid 50 mg/ml
Number of subjects: 52
Study 19223674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium‐citrate plus Gatorade (NaCIT: 170 mmol Na+L(‐1))
Number of subjects: 12
Study 19223674 — intervention group
Group type: COMPARATOR
Intervention: Gatorade (CNT)
Number of subjects: 12
Study 16001113 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 8
Study 16001113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12453280 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL Stronger Neo-Minophagen C (SNMC) administered three times a week for 12 weeks
Number of subjects: 112
Study 12453280 — intervention group
Group type: COMPARATOR
Intervention: 40 mL Stronger Neo-Minophagen C (SNMC) administered three times a week for 12 weeks
Number of subjects: 112
Study 10357743 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium glycerophosphate-supplemented infant formula (1800 mg Ca and 1390 mg P/L)
Number of subjects: 103
Study 10357743 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified infant formula (465 mg Ca and 317 mg P/L)
Number of subjects: 103
Study 7742125 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-screen radiography
Number of subjects: 100
Study 7742125 — intervention group
Group type: COMPARATOR
Intervention: Digital luminescence radiography (2 forms)
Number of subjects: 100
Study 2166429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (600 mg/day for 28 days)
Number of subjects: 51
Study 2166429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostam (20 mg antimony/kg for 20 days)
Number of subjects: 51
Study 2166429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7197583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2/week
Number of subjects: 53
Study 7197583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 90 mg/m2 every 3 weeks
Number of subjects: 53
Study 7197583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 53
Study 31565909 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation with individualized dosing to achieve 25(OH)D of 120 nmol/L for 8 weeks
Number of subjects: 42
Study 31565909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31210099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (initial loading dose of 2.5 mg/kg followed by continuous infusion for 5 days; first 10 patients received 5 mg/kg/day, subsequent 6 patients received 10 mg/kg/day)
Number of subjects: 16
Study 31210099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study 28419486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bortezomib 1.3 mg/m2 twice-weekly
Number of subjects: 104
Study 25784527 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-based resuscitation
Number of subjects: 30
Study 25784527 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (normal saline)
Number of subjects: 30
Study 24041219 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based resistance exercise programme
Number of subjects: 36
Study 24041219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic resistance exercise programme
Number of subjects: 36
Study 24041219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no strengthening activity)
Number of subjects: 36
Study 21356658 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping Her Heal intervention (delivered to partners)
Number of subjects: 9
Study 19751539 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week yoga intervention
Number of subjects: 46
Study 19751539 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 46
Study 16781115 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTP-E (enhanced parent training intervention)
Number of subjects: 74
Study 16781115 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTP-S (standard parent training intervention)
Number of subjects: 74
Study 16781115 — intervention group
Group type: COMPARATOR
Intervention: WL (waitlist control)
Number of subjects: 74
Study 15167515 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer powered by a pressure support device (PS session)
Number of subjects: 18
Study 15167515 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer activated by patient inspiratory flow (control session)
Number of subjects: 18
Study 15167515 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion skew threshold of 0.67
Number of subjects: 18
Study 11583199 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg per day during conventional-dose TIP and two doses of 500 mg during high-dose CET)
Number of subjects: 40
Study 11583199 — intervention group
Group type: COMPARATOR
Intervention: No amifostine (control group)
Number of subjects: 40
Study 11583199 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 40
Study 9589522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disordered breathing (defined as AHI > 15 per hour of sleep) in 11 of 37 patients (30%)
Number of subjects: 37
Study 9589522 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sleep hypoxia (desaturation to < 80% during the night in 7 patients, 19%)
Number of subjects: 37
Study 9589522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep variables (AHI and frequency of sleep arousals)
Number of subjects: 37
Study 7990309 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial application of a helium-neon laser beam in combination with traditional methods in the preoperative period
Number of subjects: 0
Study 2720581 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Contin (MSC) every 12 hours
Number of subjects: 14
Study 2720581 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS) every 4 hours
Number of subjects: 14
Study 31814293 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg poractant alfa
Number of subjects: 200
Study 31814293 — intervention group
Group type: COMPARATOR
Intervention: 100 mg/kg beractant
Number of subjects: 200
Study 30513014 — intervention group
Group type: EXPERIMENTAL
Intervention: TR-M-PRP plus (biomimetic peptides for hair growth)
Number of subjects: 0
Study 28559206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 international units)
Number of subjects: 52
Study 28559206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 25976288 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (14 sessions of supervised treadmill exercise and physical activity consultations)
Number of subjects: 789
Study 25976288 — intervention group
Group type: COMPARATOR
Intervention: Control (six weekly sessions of behavioural support for smoking cessation)
Number of subjects: 789
Study 25976288 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 789
Study 25976288 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 789
Study 23408034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (n = 34)
Number of subjects: 67
Study 23408034 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (n = 33)
Number of subjects: 67
Study 21296403 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 867
Study 21296403 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 867
Study 21296403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 867
Study 19392948 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit comparison standard
Number of subjects: 0
Study 19392948 — intervention group
Group type: COMPARATOR
Intervention: Explicit comparison standard
Number of subjects: 0
Study 19392948 — intervention group
Group type: COMPARATOR
Intervention: No comparison standard
Number of subjects: 0
Study 17037823 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment based on psychological models and Alcoholics Anonymous assumptions
Number of subjects: 0
Study 17037823 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment
Number of subjects: 0
Study 17037823 — intervention group
Group type: COMPARATOR
Intervention: Alcoholics Anonymous programme
Number of subjects: 0
Study 14745865 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 96
Study 14745865 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide) with high Ki-67 levels
Number of subjects: 96
Study 14745865 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide) in HER-2-negative patients
Number of subjects: 96
Study 11682037 — intervention group
Group type: COMPARATOR
Intervention: Interferon 6 MU every other day for 6 months followed by 3 MU for further 6 months (group A)
Number of subjects: 180
Study 11682037 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 6 MU every other day for 6 months followed by 3 MU for further 6 months plus amantadine 200 mg/day (group B)
Number of subjects: 180
Study 9597292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration in patients with recurrent acute tonsillitis
Number of subjects: 124
Study 9597292 — intervention group
Group type: COMPARATOR
Intervention: Fine-needle aspiration in normal tonsils
Number of subjects: 124
Study 8156739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g body weight/kg)
Number of subjects: 9
Study 8156739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1.0 g body weight/kg)
Number of subjects: 9
Study 8156739 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 9
Study 3345153 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ketorolac tromethamine solution
Number of subjects: 0
Study 3345153 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-placebo solution
Number of subjects: 0
Study 29222647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg every 3 weeks plus chemotherapy (cisplatin 50 mg/m2 or carboplatin AUC 5 plus paclitaxel 175 mg/m2 for 6-8 cycles)
Number of subjects: 27
Study 29222647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 27
Study 27542825 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Teen Leaders Avoiding Screen-time (ATLAS) obesity prevention program
Number of subjects: 361
Study 26206146 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (48 Gy in 20 fractions over a maximum of 30 days)
Number of subjects: 250
Study 26206146 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 250
Study 26206146 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 250
Study 23898559 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 100
Study 23898559 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 100
Study 21915047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of bevacizumab 2 mg (1 mg/0.04 mL)
Number of subjects: 66
Study 21915047 — intervention group
Group type: COMPARATOR
Intervention: Topical antihistamine (antazoline HCl 0.05%) and vasoconstrictor (tetrahydrozoline HCl 0.04%)
Number of subjects: 66
Study 18063230 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone intake
Number of subjects: 608
Study 18063230 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone intake > 90 mg/day
Number of subjects: 608
Study 18063230 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone intake for 6 months
Number of subjects: 608
Study 17163286 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day
Number of subjects: 107
Study 17163286 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 150 mg/day (titrated to 300 mg/day after 3 months)
Number of subjects: 107
Study 17163286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 12869833 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)-based regimen
Number of subjects: 10
Study 10516747 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2 on days 1, 8, 15, and 22 for induction; 20 mg/m2 for 4 weeks for consolidation; maintenance with oral 6 mercaptopurine 2 mg/kg/day, subcutaneous cytarabine 1 mg/kg, and oral ZVD 20 mg/m2 on day 1 and day 8 of the third month.
Number of subjects: 51
Study 10516747 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment with 4 weekly oral doses of 40 mg/m2 ZVD after induction failure.
Number of subjects: 51
Study 10516747 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation treatment with weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2.
Number of subjects: 51
Study 10516747 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with weekly oral idarubicin (ZAVEDOS-ZVD) 20 mg/m2.
Number of subjects: 51
Study 10516747 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity outcomes related to treatment.
Number of subjects: 51
Study 8612115 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 100
Study 8612115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 100
Study 8612115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2397347 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based approach (group A) with a significant family member trained as cotherapist at home
Number of subjects: 30
Study 2397347 — intervention group
Group type: COMPARATOR
Intervention: Patient-based approach (group B) where only the patient was seen and given home assignments
Number of subjects: 30
Study 373174 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate (0.5 ml of 2.5% solution)
Number of subjects: 130
Study 373174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (0.5 ml of 0.4% solution)
Number of subjects: 130
Study 31062997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 27
Study 31062997 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)
Number of subjects: 27
Study 27522121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition-specific educational program
Number of subjects: 29
Study 27522121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no program)
Number of subjects: 29
Study 25814628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inoculation of 10^4 colony-forming units of N. lactamica
Number of subjects: 310
Study 25814628 — intervention group
Group type: COMPARATOR
Intervention: Sham inoculation (control group)
Number of subjects: 310
Study 23710550 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 63
Study 23710550 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions
Number of subjects: 63
Study 22390625 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of supervised exercise training (n = 21)
Number of subjects: 40
Study 22390625 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (n = 19)
Number of subjects: 40
Study 22390625 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of supervised exercise training
Number of subjects: 40
Study 19413408 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target blood alcohol concentration of .08%)
Number of subjects: 0
Study 19413408 — intervention group
Group type: COMPARATOR
Intervention: No shock condition
Number of subjects: 0
Study 19413408 — intervention group
Group type: COMPARATOR
Intervention: Predictable shock condition
Number of subjects: 0
Study 19413408 — intervention group
Group type: COMPARATOR
Intervention: Unpredictable shock condition
Number of subjects: 0
Study 17395752 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2155
Study 17395752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2155
Study 15621558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with Type 1 diabetes mellitus
Number of subjects: 90
Study 15621558 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women
Number of subjects: 90
Study 15621558 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women
Number of subjects: 90
Study 15621558 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pregnant women
Number of subjects: 90
Study 15621558 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic pregnant women
Number of subjects: 90
Study 15621558 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic pregnant women in 3rd trimester
Number of subjects: 90
Study 14607696 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) within 24 hours after admission, combined with supportive treatment and traditional Chinese medicine.
Number of subjects: 45
Study 14607696 — intervention group
Group type: COMPARATOR
Intervention: Non-ERCP treatment, combined with supportive treatment and traditional Chinese medicine.
Number of subjects: 45
Study 14607696 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP treatment in mild acute GP patients.
Number of subjects: 45
Study 14607696 — intervention group
Group type: COMPARATOR
Intervention: Non-ERCP treatment in mild acute GP patients.
Number of subjects: 45
Study 10320861 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (20 half price sessions over 10 weeks at a leisure centre)
Number of subjects: 142
Study 10320861 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherers in the exercise group
Number of subjects: 142
Study 10320861 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study 7917359 — intervention group
Group type: EXPERIMENTAL
Intervention: POCAL (prednisone, vincristine, doxorubicin, Ara‐C, thioguanine)
Number of subjects: 22
Study 7917359 — intervention group
Group type: EXPERIMENTAL
Intervention: MEA (mitoxantrone, etoposide, Ara‐C)
Number of subjects: 22
Study 7917359 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD (daunorubicin, Ara‐C, thioguanine)
Number of subjects: 22
Study 7917359 — intervention group
Group type: EXPERIMENTAL
Intervention: LIP (life ingredient profile)
Number of subjects: 22
Study 3658278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1-g dose)
Number of subjects: 199
Study 3658278 — intervention group
Group type: COMPARATOR
Intervention: Cefonicid (1-g dose)
Number of subjects: 199
Study 31588607 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise intervention for 12 weeks
Number of subjects: 0
Study 29780106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medications on dialysis days
Number of subjects: 700
Study 29780106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medications on nondialysis days
Number of subjects: 700
Study 29780106 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of oral medications
Number of subjects: 700
Study 29780106 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of oral medications
Number of subjects: 700
Study 29780106 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate binders
Number of subjects: 700
Study 29780106 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug burden comparison
Number of subjects: 700
Study 27142865 — intervention group
Group type: EXPERIMENTAL
Intervention: Low health literacy group
Number of subjects: 739
Study 27142865 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient physical activity
Number of subjects: 739
Study 27142865 — intervention group
Group type: EXPERIMENTAL
Intervention: Being overweight
Number of subjects: 739
Study 27142865 — intervention group
Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 739
Study 27142865 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 739
Study 25403470 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 400
Study 25403470 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 400
Study 25403470 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 400
Study 25403470 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 400
Study 23733796 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic bag intervention
Number of subjects: 104
Study 23733796 — intervention group
Group type: COMPARATOR
Intervention: Standard thermoregulation care
Number of subjects: 104